Analysts think SLNO stock price could increase by 61%
Apr 10, 2025, 11:25 AM
21.41%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
11 analysts think SLNO stock price will increase by 61.19%. The current median analyst target is $102.00 compared to a current stock price of $63.28. The lowest analysts target is $75.75 and the highest analyst target is $129.15.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.